Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 324

1.

The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment.

Montessori ML, Scheele WH, Netelenbos JC, Kerkhoff JF, Bakker K.

Osteoporos Int. 1997;7(1):52-8.

PMID:
9102064
3.

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

Miller PD, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, Ross PD, Jackson RD, Hoseyni MS, Schoenfeld SL, Valent DJ, Chesnut CH 3rd.

Am J Med. 1997 Dec;103(6):468-76. Erratum in: m J Med 1998 Jun;104(6):608.

PMID:
9428829
4.

Effects of combined treatment with etidronate, nandrolone-decanoate and calcium on bone mineral density in postmenopausal women.

Bolanca S, Korsić M, Dekanić D, Cvijetić S.

Acta Med Croatica. 1998;52(3):159-63.

PMID:
9818438
5.
6.

Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy.

Cortet B, Béra-Louville A, Gauthier P, Gauthier A, Marchandise X, Delcambre B.

Joint Bone Spine. 2001 Oct;68(5):410-5.

PMID:
11707007
7.

A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.

Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY.

Osteoporos Int. 1997;7(5):488-95.

PMID:
9425508
8.

Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.

Palomba S, Orio F Jr, Manguso F, Falbo A, Russo T, Tolino A, Tauchmanovà L, Colao A, Doldo P, Mastrantonio P, Zullo F.

Osteoporos Int. 2005 Sep;16(9):1141-9. Epub 2005 Jun 1.

PMID:
15928801
9.

Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial.

Guañabens N, Farrerons J, Perez-Edo L, Monegal A, Renau A, Carbonell J, Roca M, Torra M, Pavesi M.

Bone. 2000 Jul;27(1):123-8.

PMID:
10865219
11.

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.

Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC 3rd, Yanover MJ, et al.

N Engl J Med. 1990 Jul 12;323(2):73-9.

12.

A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.

Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H; Risedronate Phase III Research Group.

Osteoporos Int. 2002 Dec;13(12):971-9.

PMID:
12459940
13.

Intermittent Etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist.

Zamberlan N, Castello R, Gatti D, Rossini M, Braga V, Fracassi E, Adami S.

Osteoporos Int. 1997;7(2):133-7.

PMID:
9166393
14.

Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures.

Anderson FH, Francis RM, Bishop JC, Rawlings DJ.

Age Ageing. 1997 Sep;26(5):359-65.

PMID:
9351480
15.

Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.

Ringe JD, Farahmand P, Faber H, Dorst A.

Rheumatol Int. 2009 Jan;29(3):311-5. doi: 10.1007/s00296-008-0689-2. Epub 2008 Sep 2.

PMID:
18762944
16.

Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.

Storm T, Kollerup G, Thamsborg G, Genant HK, Sørensen OH.

J Rheumatol. 1996 Sep;23(9):1560-4.

PMID:
8877926
17.

Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.

Sato S, Ohosone Y, Suwa A, Yasuoka H, Nojima T, Fujii T, Kuwana M, Nakamura K, Mimori T, Hirakata M.

J Rheumatol. 2003 Dec;30(12):2673-9.

PMID:
14719212
19.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
20.

Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.

Fogelman I, Herd RJ, Blake GM, Balena R.

Calcif Tissue Int. 2000 May;66(5):348-54.

PMID:
10773104

Supplemental Content

Support Center